Categories
General Health United States World

Glioblastoma Treated with Immunotherapy Breakthrough

An Australian brain cancer doctor was diagnosed with incurable stage IV brain cancer in 2023. Doctor Richard Scolyer treated his brain cancer using an experimental immunotherapy that he and his team developed. He has now been cancer-free for a year and with this immunotherapy, he invented the treatment of melanoma skin cancer for the first time in the globe, according to BBC.

Dr. Scolyer (57) was diagnosed with glioblastoma (GBM), an aggressive cancer whose cause is unknown, and the survival rate of the average time is 12-18 months in Australia. However, his latest MRI showed that there is no recurrence of the tumor.

The esteemed pathologist’s experimental therapy is based on his pioneering melanoma research. According to NCBI, “there is a small number of survivors after a long period of years on their surgical removals.” It is a very aggressive brain cancer that affects more than 300,000 people worldwide every year.

In America, the five-year survival rate for glioblastoma patients is 6.9%, and the average length of survival is about 8 months. According to brain tumor research.com, “as co-director of the Melanoma Institute Australia, over the past decade the pair’s research on immunotherapy, which uses the body’s immune system to attack cancer cells, has dramatically improved outcomes for advanced melanoma patients globally. Half are now essentially cured, up from less than 10%.”

With more and more technology developing, research efforts are being made of significant efficacy, and secrets will be revealed. Soon, we will get to know the major causes of brain cancer like glioblastoma or other incurable cancers as well—ode to all the health professionals whose efforts have no boundaries to reach out.

Coree ILBO copyright © 2013-2024, All rights reserved. This material may not be published, broadcast, rewritten, or redistributed in whole or part without the express written permission.

Leave a Reply

Your email address will not be published. Required fields are marked *

Confirm that you are not a bot - select a man with raised hand: